Clinical Scenario: A 57-Year-Old Woman With Metastatic Breast Cancer


Two oncologists present the clinical scenario of a 57-year-old woman with metastatic HER2-positive breast cancer to discuss their approach for incorporating recent research into clinical decision making around systemic therapy.

The video opens with Laura Spring, a breast medical oncologist from Mass General Cancer Center and Harvard Medical School, welcoming viewers to a program on interpreting the latest data for breast cancer treatment approaches. She introduces her colleague, Dr. Manali Bhave, a breast medical oncologist from Emory University and director of the phase one unit.

Bhave presents a hypothetical patient case of a 57-year-old healthy woman diagnosed with invasive ductal carcinoma in her left breast after a 4cm mass was found on mammogram. The tumor was estrogen, progesterone and HER2 positive with an IHC of 3+. Scans revealed metastatic disease with three 3cm liver lesions and a solitary lung lesion. A liver biopsy confirmed metastatic triple positive breast cancer.

The patient received 6 cycles of docetaxel, trastuzumab, and pertuzumab (THP) followed by maintenance HP. She had a good response with the breast mass shrinking and complete resolution of the liver lesions initially. However, after some time on maintenance HP, she progressed with recurrence of 3 new liver lesions, though her liver enzyme levels remained normal.

Bhave and Spring proceed to discuss how they would approach treating this patient's recurrent metastatic HER2+ breast cancer, incorporating the latest clinical data and pivotal trials in their decision-making process. The case illustrates their real-world application of recent research advances.

This summary was AI-generated and edited for clarity.

Related Videos
Video 2 - "Targeting RET Fusion in Brain Tumor"
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 6 - "Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer"
Video 5 - "Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC"
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Carlos Arteaga, MD
Video 2 - "NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer"